U.S. Veterinary Neurodegenerative Disease Diagnostics Market To Reach $158.44 Million By 2030

U.S. Veterinary Neurodegenerative Disease Diagnostics Market Growth & Trends

The U.S. veterinary neurodegenerative disease diagnostics market size is expected to reach USD 158.44 million by 2030, registering a CAGR of 7.3% from 2025 to 2030, according to a new report by Grand View Research, Inc. The key factors driving the market growth are growing research initiatives, the rising prevalence of neurodegenerative diseases, and support initiatives. The increasing prevalence of neurodegenerative diseases in animals is fueling rapid growth in the veterinary diagnostics sector in the U.S. Conditions like Canine Cognitive Dysfunction (CCD) and Feline Cognitive Dysfunction (FCD) are becoming more widely recognized, with evidence suggesting that nearly 73% of senior dogs and 50% of senior cats exhibit signs of cognitive decline. This heightened awareness among pet owners and veterinarians has driven demand for early and accurate diagnostic tools.

Technological innovations are propelling this sector forward. AI-enhanced imaging techniques now offer more precise interpretation of X-rays, ultrasounds, and MRIs, enabling the earlier detection of neurodegenerative diseases. Meanwhile, advanced molecular diagnostics-including PCR-based assays and next-generation sequencing-provide more accurate identification of disease markers, reflecting a broader trend toward precision medicine.

Research has also evolved significantly. Specific genetic markers once considered promising for neurodegenerative disease diagnosis have been dismissed based on newer studies, underscoring the importance of adaptable diagnostic technologies that can keep pace with shifting scientific insights. Regulatory frameworks, such as those used in bovine spongiform encephalopathy (BSE) surveillance, demonstrate the crucial role of government oversight in disease control. These programs highlight how comprehensive monitoring and robust diagnostics are vital for maintaining animal and human health.

Beyond surveillance, progress in biomarker discovery, imaging technologies, and neurobehavioral testing continues to transform the diagnostic landscape. These advancements support earlier intervention and better disease management, driving the sector toward continuous innovation. Public awareness campaigns and advocacy efforts have also played a pivotal role, boosting investment in research and development. This surge of interest in diagnostic testing reflects a shared priority-across both veterinary and human medicine-to address neurodegenerative diseases more effectively.

 Request a free sample copy or view report summary: U.S. Veterinary Neurodegenerative Disease Diagnostics Market Report

U.S. Veterinary Neurodegenerative Disease Diagnostics Market Report Highlights

• Based on product, consumables, reagents, and kits segment held the largest revenue share in 2024, and is expected to grow at the fastest CAGR over the forecast period. This dominance can be attributed to these products being essential for routine testing, offering cost-effective, convenient, and standardized solutions for veterinarians. These products are frequently used in genetic screening, biomarker assays, and immunoassays and are key tools for diagnosing conditions like canine cognitive dysfunction.

• Based on diagnostic tests, the imaging segment held the largest market share of 45.6% in 2024. This segment consists of imaging diagnostic tests such as MRI and CT scans, whose dominance can be attributed to their ability to provide detailed, high-resolution images of the brain, which aid in detecting subtle structural changes. They help differentiate between overlapping clinical signs and are non-invasive, making them safe for repeated use.

• Based on animal type, the companion animal segment dominated the U.S. veterinary neurodegenerative disease diagnostics industry in 2024 and is also expected to grow at the fastest CAGR over the forecast period. This segment, which includes animals such as canines, felines, equines, etc., is mainly driven by rising pet ownership and increased awareness of neurodegenerative conditions like degenerative myelopathy in dogs, cerebellar abiotrophy in horses, and canine cognitive dysfunction.

• Based on indication, the cognitive dysfunction segment held the largest revenue share in 2024 and is expected to grow at the fastest CAGR over the forecast period. In the U.S., these diagnostic tests are most commonly conducted for cognitive dysfunction syndrome (CDS) primarily because it is highly prevalent among aging companion animals, especially dogs and cats, constituting the largest segment of pet ownership.

U.S. Veterinary Neurodegenerative Disease Diagnostics Market Segmentation

Grand View Research has segmented the U.S. veterinary neurodegenerative disease diagnostics market based on animal type, product, diagnostic test, indication, and end-use:

U.S. Veterinary Neurodegenerative Disease Diagnostics Product Outlook (Revenue, USD Million, 2018 - 2030)

• Consumables, Reagents & Kits

• Equipment & Instruments

U.S. Veterinary Neurodegenerative Disease Diagnostics Diagnostic Tests Outlook (Revenue, USD Million, 2018 - 2030)

• Imaging

  • MRI (Magnetic Resonance Imaging)

  • CT (Computed Tomography)

  • Others

• Biomarker Diagnostic Tests

  • CSF (Cerebrospinal Fluid) biomarkers

  • Blood-based biomarkers

  • Others

• Others

U.S. Veterinary Neurodegenerative Disease Diagnostics Animal Type Outlook (Revenue, USD Million, 2018 - 2030)

• Livestock

  • Sheep

  • Cattle

  • Others

• Companion

  • Canine

  • Feline

  • Equine

  • Others

U.S. Veterinary Neurodegenerative Disease Diagnostics Indication Outlook (Revenue, USD Million, 2018 - 2030)

• Cognitive Dysfunction

• Cerebellar Abiotrophy

• Spongiform Encephalopathies

• Others

U.S. Veterinary Neurodegenerative Disease Diagnostics End-use Outlook (Revenue, USD Million, 2018 - 2030)

• Veterinary Hospitals and Clinics

• Veterinary Diagnostic Laboratories

• Others

List of Key Players in the U.S. Veterinary Neurodegenerative Disease Diagnostics Market

• Zoetis

• Virbac

• Life Diagnostics

• ACUVET BIOTECH

• Merck & Co., Inc.

• IDEXX Laboratories, Inc.

• MI:RNA Diagnostics Ltd.

• Mercodia AB

• Antech Diagnostics, Inc.

• Avacta Animal Health Limited